Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,gmtOffSetMilliseconds,esgPopulated,tradeable,market,exchange,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,priceHint,marketState,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,fax,industry,address2
t0,FYB.DE,67535704,11000000,,,-2226789,,-2271789,2568958,1513843,-2203146,-2203146,914576,-38462,,,,45000,8858766,11061912,7344923,-23642,,-2271789,-2271789,223476,7563396,68035015,1146292,75598409,11000000,130273,-19953512,397788,275835,76988527,418351,42008839,7165608,280000,76988527,3500798,50506700,20673249,237878,6894321,1235389,4483833,637750,-146250,12836350,134500,12875000,11006550,-1684050,233350,650,-806550,-38650,388691,-103400,43341092,en-US,US,EQUITY,False,Delayed Quote,EUR,-0.9615385,50.3 - 52.8,52.0,51.9,52.2,200,280,finmb_84155935,XETRA,Formycon AG,EUR,7088,6387,7200000,False,False,de_market,GER,-0.539,0.04,6.185,54.898613,-3.398613,-0.061907083,60.786266,-9.286266,-0.15276915,566499968,1287.5,8.326596,15,Europe/Berlin,CEST,51.5,1630510573,-0.5,52.8,52.8,50.3,3083,FORMYCON AG,2,POSTPOST,0,26.7,1.076613,24.8 - 79.8,-28.300003,-0.3546366,24.8,79.8,1621215018,1632221940,1632744000,1.18,,,79.8,24.8,54.9,60.79,7.09k,6.39k,11M,,9.5M,38.79%,11.23%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Dec 31, 2020",-17.31%,-16.78%,-5.56%,-10.19%,34.23M,3.11,11.20%,8.76M,-4.83M,-5.93M,-0.54,,42.25M,3.84,,,7.05,6.18,-5.1M,-3.4M,Value,82152,Healthcare,103,"Formycon AG develops and markets biosimilar products. The company's product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. It is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",Planegg,49 89 864667 100,Germany,http://www.formycon.com,86400,Fraunhoferstrasse 15,49 89 864667 110,Biotechnology,Martinsried
t-1,FYB.DE,67535704,11000000,,,-2226789,,-2271789,2568958,1513843,-2203146,-2203146,914576,-38462,,,,45000,8858766,11061912,7344923,-23642,,-2271789,-2271789,223476,7563396,68035015,1146292,75598409,11000000,130273,-19953512,397788,275835,76988527,418351,42008839,7165608,280000,76988527,3500798,50506700,20673249,237878,6894321,1235389,4483833,637750,-146250,12836350,134500,12875000,11006550,-1684050,233350,650,-806550,-38650,388691,-103400,43341092,en-US,US,EQUITY,False,Delayed Quote,EUR,-0.9615385,50.3 - 52.8,52.0,51.9,52.2,200,280,finmb_84155935,XETRA,Formycon AG,EUR,7088,6387,7200000,False,False,de_market,GER,-0.539,0.04,6.185,54.898613,-3.398613,-0.061907083,60.786266,-9.286266,-0.15276915,566499968,1287.5,8.326596,15,Europe/Berlin,CEST,51.5,1630510573,-0.5,52.8,52.8,50.3,3083,FORMYCON AG,2,POSTPOST,0,26.7,1.076613,24.8 - 79.8,-28.300003,-0.3546366,24.8,79.8,1621215018,1632221940,1632744000,1.18,,,79.8,24.8,54.9,60.79,7.09k,6.39k,11M,,9.5M,38.79%,11.23%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Dec 31, 2020",-17.31%,-16.78%,-5.56%,-10.19%,34.23M,3.11,11.20%,8.76M,-4.83M,-5.93M,-0.54,,42.25M,3.84,,,7.05,6.18,-5.1M,-3.4M,Value,82152,Healthcare,103,"Formycon AG develops and markets biosimilar products. The company's product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. It is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",Planegg,49 89 864667 100,Germany,http://www.formycon.com,86400,Fraunhoferstrasse 15,49 89 864667 110,Biotechnology,Martinsried
t-2,FYB.DE,46303324,11000000,,,-691261,,-691063,2446940,2866446,-667583,-667583,862934,-14333,,,,-198,8254704,8922286,5388258,-23679,,-691063,-691063,170627,5351322,46828596,690607,52179917,10000000,146774,-15409931,571367,354645,52238527,631507,19998535,4779955,370000,52238527,3670476,26679413,20673249,235470,5864935,433699,2920651,337250,-177750,-14350,134500,12875000,-1060050,-867950,224150,350,-434950,-14350,-303338,-175600,21899458,en-US,US,EQUITY,False,Delayed Quote,EUR,-0.9615385,50.3 - 52.8,52.0,51.9,52.2,200,280,finmb_84155935,XETRA,Formycon AG,EUR,7088,6387,7200000,False,False,de_market,GER,-0.539,0.04,6.185,54.898613,-3.398613,-0.061907083,60.786266,-9.286266,-0.15276915,566499968,1287.5,8.326596,15,Europe/Berlin,CEST,51.5,1630510573,-0.5,52.8,52.8,50.3,3083,FORMYCON AG,2,POSTPOST,0,26.7,1.076613,24.8 - 79.8,-28.300003,-0.3546366,24.8,79.8,1621215018,1632221940,1632744000,1.18,,,79.8,24.8,54.9,60.79,7.09k,6.39k,11M,,9.5M,38.79%,11.23%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Dec 31, 2020",-17.31%,-16.78%,-5.56%,-10.19%,34.23M,3.11,11.20%,8.76M,-4.83M,-5.93M,-0.54,,42.25M,3.84,,,7.05,6.18,-5.1M,-3.4M,Value,82152,Healthcare,103,"Formycon AG develops and markets biosimilar products. The company's product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. It is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",Planegg,49 89 864667 100,Germany,http://www.formycon.com,86400,Fraunhoferstrasse 15,49 89 864667 110,Biotechnology,Martinsried
t-3,FYB.DE,46303324,11000000,,,-691261,,-691063,2446940,2866446,-667583,-667583,862934,-14333,,,,-198,8254704,8922286,5388258,-23679,,-691063,-691063,170627,5351322,46828596,690607,52179917,10000000,146774,-15409931,571367,354645,52238527,631507,19998535,4779955,370000,52238527,3670476,26679413,20673249,235470,5864935,433699,2920651,337250,-177750,-14350,134500,12875000,-1060050,-867950,224150,350,-434950,-14350,-303338,-175600,21899458,en-US,US,EQUITY,False,Delayed Quote,EUR,-0.9615385,50.3 - 52.8,52.0,51.9,52.2,200,280,finmb_84155935,XETRA,Formycon AG,EUR,7088,6387,7200000,False,False,de_market,GER,-0.539,0.04,6.185,54.898613,-3.398613,-0.061907083,60.786266,-9.286266,-0.15276915,566499968,1287.5,8.326596,15,Europe/Berlin,CEST,51.5,1630510573,-0.5,52.8,52.8,50.3,3083,FORMYCON AG,2,POSTPOST,0,26.7,1.076613,24.8 - 79.8,-28.300003,-0.3546366,24.8,79.8,1621215018,1632221940,1632744000,1.18,,,79.8,24.8,54.9,60.79,7.09k,6.39k,11M,,9.5M,38.79%,11.23%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Dec 31, 2020",-17.31%,-16.78%,-5.56%,-10.19%,34.23M,3.11,11.20%,8.76M,-4.83M,-5.93M,-0.54,,42.25M,3.84,,,7.05,6.18,-5.1M,-3.4M,Value,82152,Healthcare,103,"Formycon AG develops and markets biosimilar products. The company's product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases that has completed Phase III clinical trials; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. It is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.",Planegg,49 89 864667 100,Germany,http://www.formycon.com,86400,Fraunhoferstrasse 15,49 89 864667 110,Biotechnology,Martinsried
